Parameter | No. of subjects (%)* |
---|---|
N | 240 |
Mean age | Â |
   Years, SD | 43.9 (10.9) |
Gender | Â |
   Male | 156 (65.0%) |
   Female | 84 (35.0%) |
Race | Â |
   Asian | 1 (0.4%) |
   Black or African American | 151 (62.9%) |
   Native Hawaiian or other Pacific Islander | 1 (0.4%) |
   White | 80 (33.3%) |
   Other | 7 (2.9%) |
DSM-IV Schizophrenia subtype diagnosis | Â |
   295.10 Disorganized type | 4 (1.7%) |
   295.20 Catatonic type | 0 |
   295.30 Paranoid type | 125 (52.1%) |
   295.60 Residual type | 2 (0.8%) |
   295.70 Schizoaffective disorder | 89 (37.1%) |
   295.90 Undifferentiated type | 21 (8.8%) |
Preswitch antipsychotic agent at study start | Â |
   Quetiapine | 62 (25.8%) |
   Risperidone | 51 (21.3%) |
   Aripiprazole | 44 (18.3%) |
   Ziprasidone | 27 (11.3%) |
   Olanzapine | 24 (10.0%) |
   Paliperidone | 9 (3.8%) |
   Iloperidone | 4 (1.7%) |
   Asenapine | 2 (0.8%) |
   First-generation antipsychotic | 17 (7.1%) |
Treatment with concomitant lithium, valproate or lamotrigine | 34 (16.2%) |
Treatment with concomitant antidepressant | 104 (43.3%) |
Mean age (SD) at initial onset of schizophrenia or schizoaffective disorder, years | 25.1 (9.3) |
Mean positive and negative syndrome scale total score (SD) | 68.9 (13.8) |
Mean clinical global impression severity score (SD) | 3.7 (0.5) |